Navigation Links
Moffitt-USF head toward first human trials of anti-cancer drug that targets protein AKT

H. Lee Moffitt Cancer Center & Research Institute, working in partnership with the University of South Florida (USF), has discovered a new use for an old, previously discredited anti-cancer drug that could add another weapon in the arsenal against several cancers, including tumors of the breast, ovary, colon, skin and prostate.

The compound, tricirbine, was tested at various cancer centers from 1982 to 1996 and found to inhibit some cancers, but researchers failed to determine why. The Moffitt-USF team discovered that tricirbine works only against tumors in which the cancer-causing Akt protein is abundant and/or abnormally active.

"These tumors are addicted to hyperactive Akt and cannot survive without it," explains Saïd Sebti, Ph.D., Moffitt's Manuel and Adeline Garcia Professor, Leader of the Drug Discovery Program and Associate Director of Moffitt Research Institute. "What we discovered is a tailored therapy for tumors with a specific molecular signature."

Resurrecting tricirbine may be promising for patients with ovarian cancer, for instance, because "40 percent of women with ovarian cancer have tumors with high levels of active Akt," according to Sebti.

"To our knowledge, this is the first Akt inhibitor headed toward clinical trials," said Jin Cheng, MD, PhD, USF Professor of Pathology and Interdisciplinary Oncology.

Cheng and Sebti's study results were published in the journal Cancer Research.

VioQuest Pharmaceuticals Inc. (VQPH) of New Jersey is acquiring the licensing rights to the compound from USF through its merger with Greenwich Therapeutics Inc. and is planning clinical trials with Moffitt. The trials are expected to start within six to eight months. Patients will be selected for the trials based on whether their tumors have hyperactive Akt, which can be determined by a simple slide-stain test of tumor tissue.

Because tricirbine has previously been investigated in humans, the hypothesis-driven c linical trials planned at Moffitt can move directly into a PhaseI/II trial.

With the step-up of functional-genomics research at Moffitt and around the country, the advent of "customized medicine" has been heralded in headlines and at medical conferences. The clinical trial of this Akt-inhibitor is a concrete step toward that reality. Sebti says, "The beauty of this trial is that it's molecular therapy, based on the blueprint of the tumor cell."


'"/>

Source:University of South Florida Health Sciences Center


Related biology news :

1. Unchecked DNA replication drives earliest steps toward cancer
2. Virologists make major step towards understanding the process of HIV infection
3. Cats indifference towards sugar explained
4. A step toward the $1,000 personal genome using readily available lab equipment
5. A new step towards an AIDS vaccine
6. New GM mosquito sexing technique is step towards malaria control, report scientists
7. Novel method reveals how menthol discovery could point towards new or improved pain therapies
8. Scientists make first step towards holy grail of crystallography
9. Salk researchers make fast strides towards understanding how our body controls walking
10. Illegal trade is propelling rare turtle toward extinction, new report
11. Iraqs marshes show progress toward recovery
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/5/2018)... ... 04, 2018 , ... Urological Associates of Southern Arizona today ... Excellence. The designation recognizes that Dr. Choi has achieved a high level of ... care for men suffering from symptoms associated with Benign Prostatic Hyperplasia or BPH. ...
(Date:11/29/2018)... (PRWEB) , ... November 29, 2018 , ... ... in Semba Biosciences with the intention of acquiring full ownership. The transaction was ... Agreement was executed on November 14, 2018. “We are extremely pleased to team ...
(Date:11/27/2018)... ... November 27, 2018 , ... LabArchives ... worked together to integrate the LabArchives Classroom Edition with Current Protocols Essential Laboratory ... be available beginning January of 2019. , The integration of LabArchives ...
Breaking Biology News(10 mins):
(Date:11/20/2018)... , ... November 20, 2018 , ... Dr. Steven White ... for gingivitis at their office in Cornelius, NC. This common infection, left untreated, can ... in practice, along with special training and certification in laser dentistry, Drs. White and ...
(Date:11/13/2018)... ... ... Renowned Honolulu veterinarian, Dr. Patrick Leadbeater, has begun offering VetStem Regenerative ... Kahala Pet Hospital on Oahu, is a skilled surgeon who has been ... of Kauai on an almost weekly basis to perform surgery at Kapaa Animal ...
(Date:11/13/2018)... ... November 12, 2018 , ... Dr. Dan Myers, a ... Springs, now welcomes new patients for MTM® Clear Aligners. Offering a variety of ... braces in the Sandy Springs and Alpharetta areas. Constantly on the forefront of ...
(Date:11/13/2018)... ... November 13, 2018 , ... , Park Systems, world leader ... With the increasingly growing demand for AFM technology in China, Park Systems has decided ... opening an office in Beijing equipped with Park AFM. , The Grand Opening of ...
Breaking Biology Technology: